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2746interstage myocardial infarction observed with staged CAS-OHS
(in most cases, PCI can be safely performed ﬁrst) and periopera-
tive stroke observed with combined CEA-OHS (1). In this regard,
because the majority of stroke during OHS are related to aortic
cross-clamping, an off-pump surgical approach would be advisable,
as recently suggested (4). Finally, patients not suitable for PCI may
take advantage of another option; that is, a simultaneous hybrid
revascularization by CAS immediately followed by coronary artery
bypass graft, which displayed a cumulative 30-day and 12-month
event rate of 4% and 7%, respectively, after a tailored antith-
rombotic strategy (5).*Fabrizio Tomai, MD
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the SHARP study. J Am Coll Cardiol Intv 2009;2:393–401.Figure 1 Combined Event Risk Versus Trough ConcentrationsLearning More From the
Dabigatran Concentrations
in the RE-LY StudyCombined event risk compared with trough concentrations for a 72-year-old
male with atrial ﬁbrillation, diabetes mellitus, and previous stroke. The shaded
zone indicates a possible target concentration range. The lower limit is higher than
indicated by the curve because of the greater uncertainty in the event risk–
concentration relationship at the lower concentrations. The horizontal bars
indicate the 10th, 50th, and 90th percentiles of trough concentrations in the
RE-LY study according to dabigatran etexilate dose rate (1).We read with great interest the paper by Reilly et al. (1), which
demonstrated that higher trough plasma dabigatran concentrations
were associated with: 1) decreasing risk of stroke/systemic embolic
event (SEE); and 2) increasing major bleeding risk in the RE-LY
(Randomized Evaluation of Long-Term Anticoagulation Therapy)trial (2). The paper provides useful insights into the relationship
between dabigatran exposure and clinical events but raises several
questions.
1. Time lag from blood samples to events.
The dabigatran concentrations reported by Reilly et al. (1) were
from blood samples that were mostly collected 1 month after enroll-
ment. In contrast, the majority of the strokes/SEE in the RE-LY
study occurred >12 months after enrollment (2). This difference
limits the inferences that can be drawn from the observed relationship
between dabigatran concentrations and adverse events, because of
intraindividual changes during the time lag (e.g., altered renal func-
tion [3]) or addition/withdrawal of interacting medicines (4–7).
Could the temporal relationship between events and blood
samples be described more speciﬁcally? Furthermore, was the
correlation between trough concentrations and events stronger for
those with a shorter time lag?
2. Variability in trough concentrations.
In the RE-LY study, a subgroup of those on dabigatran etexilate
contributed additional blood samples at 3, 6, and 12 months after
enrollment (1). These data could provide insights into intra-
individual variability in trough plasma dabigatran concentrations
over time.
3. Therapeutic index.
According to Reilly et al. (1), their data demonstrated that
dabigatran has a wide therapeutic index. This is a strong claim,
which we question. Data in their Table 1 and Figure 2 show that
for a 72-year-old male with atrial ﬁbrillation, diabetes mellitus, and
previous stroke, there was a 3-fold increase in risk of major bleeding
events between the 10th and 90th percentiles of trough concen-
trations. Furthermore, they found that the ischemic stroke/SEE
risk declined steeply at low concentrations, with little additional
beneﬁt from higher concentrations. These data actually allow a
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2747more formal development of a possible target trough concentration
range.
An example of a range for this individual may be derived by
adjusting the lines of best ﬁt of the event risk–concentration curves
by using event weighting according to the hazard ratios of death
described by Eikelboom et al. (8) and then combining the lines of
best ﬁt (Fig. 1). Note that for the patient described here, the
therapeutic range is relatively narrow compared with the 10th to
90th percentiles of trough concentrations and would certainly not
be considered a wide therapeutic range.
4. Trough concentrations outside the 10th and 90th percentiles.
By deﬁnition, 20% of individuals treated with dabigatran etex-
ilate in the RE-LY study had concentrations outside the 10th to
90th percentiles of trough plasma dabigatran concentrations. Did
the outcomes for these individuals differ from the rest of the
cohort? Dose adjustment to “improve” the drug exposure for these
20% of patients may be beneﬁcial. Could the authors describe the
characteristics of the individuals with trough plasma dabigatran
concentrations that were below the 10th percentile and above the
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Between High-Density
Lipoprotein Cholesterol
and Inﬂammatory Response
in Cardiovascular DiseaseIn the recently published post-hoc analysis from the COURAGE
(Clinical Outcomes Utilizing Revascularization and Aggressive
Drug Evaluation) trial, low high-density lipoprotein cholesterol
(HDL-C) levels remained a powerful and independent predictor
of cardiovascular (CV) risk in 2,193 patients with stable ischemic
heart disease (1). This ﬁnding was also conﬁrmed in patients with
low-density lipoprotein cholesterol (LDL-C) levels <70 mg/dl.
However, both in primary prevention, as in the JUPITER
(Justiﬁcation for the Use of Statins in Primary Prevention: An
Intervention Trial Evaluating Rosuvastatin) trial (2), as in sec-
ondary prevention (3), potent statin therapy may lead to no
relation between HDL-C and residual CV risk. Furthermore, the
AIM-HIGH (Atherothrombosis Intervention in Metabolic
Syndrome With Low HDL/High Triglycerides: Impact on
Global Health Outcomes) Investigators have shown that there
was no incremental clinical beneﬁt from the addition of niacin to
statin therapy despite a signiﬁcant and sustained increase in
HDL-C (4).
We feel that the missing link to understanding this unclear
relation of HDL-C and residual CV risk in patients using intensive
lipid-lowering medication relies on the degree of systemic inﬂam-
mation. In fact, although HDL-C modulates cholesterol avail-
ability in the cell membrane, which promotes reverse cholesterol
transport (HDL-C’s main antiatherogenic effect), it also inﬂuences
the immune response, the hematopoietic stem cells maturation,
and ultimately the leukocyte number (5–7). HDL-C also plays a
key role in the humoral innate immune response, as HDL-C in-
duces the long pentraxin 3 (PTX3), and PTX3 levels are increased
in animal models with genetically increased HDL levels. PTX3
deﬁciency then results in increased inﬂammation and bone marrow
monocytosis (8). Again, in a prospective multiethnic trial that
enrolled patients with ST-segment elevation myocardial infarction
(9), high levels of systemic inﬂammation, deﬁned by increased
levels of interleukin-6 and C-reactive protein (CRP) within 6 h of
the onset of symptoms, were associated with a signiﬁcant reduction
in HDL-C compared with patients with ST-segment elevation
myocardial infarction and low levels of systemic inﬂammatory
markers (10). Furthermore, inﬂammation induces major changes in
HDL-C composition. Mediators of inﬂammation such as tumor
necrosis factor–alpha and interleukin-6 induce expression of serum
amyloid A and group IIA secretory phospholipase A2, which
dramatically alter HDL apolipoprotein content and levels, respec-
tively (7). All this evidence suggests a profound link between in-
ﬂammatory response in patients with atherosclerosis and the
levels and composition of HDL-C. In our opinion, this link is
underexplored in the subanalyses of large clinical trials aimed at
increasing HDL-C levels and in studies on the predictive value of
HDL-C levels on residual CV risk.
